Key points are not available for this paper at this time.
These results support the contention that Akt activation is a mechanism of chemotherapeutic resistance in B-pre ALL and suggest that Akt can be a therapeutic target for the treatment of relapsed or refractory pediatric B-pre ALL.
Morishita et al. (Mon,) studied this question.